PDF(Pubmed)
Abstract：
The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with endometrial cancer was published in 2022. It was therefore decided, by both the ESMO and the Indian Society of Medical and Paediatric Oncology (ISMPO), to convene a virtual meeting in July 2022 to adapt the ESMO 2022 guidelines to take into account the variations in the management of endometrial cancer in Asia. These guidelines represent the consensus opinion of a panel of Asian experts representing the oncological societies of China (CSCO), India (ISMPO), Indonesia (ISHMO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), the Philippines (PSMO), Singapore (SSO), Taiwan (TOS) and Thailand (TSCO). Voting was based on scientific evidence and was conducted independently of the current treatment practices and treatment access constraints in the different Asian countries, which were discussed when appropriate. The aim of this guideline manuscript is to provide guidance for the optimisation and harmonisation of the management of patients with endometrial cancer across the different regions of Asia, drawing on the evidence provided by Western and Asian trials whilst respecting the variations in clinical presentation, diagnostic practices including molecular profiling and disparities in access to therapeutic options, including drug approvals and reimbursement strategies.
摘要：
最新版本的欧洲医学肿瘤学会（ESMO）临床实践指南的诊断，子宫内膜癌患者的治疗和随访于2022年发表.因此决定,由ESMO和印度医学和儿科肿瘤学会（ISMPO），在2022年7月召开虚拟会议，以适应ESMO2022指南，以考虑亚洲子宫内膜癌管理的变化。这些指南代表了代表中国肿瘤学会（CSCO）的亚洲专家小组的共识意见，印度(ISMPO),印度尼西亚(ISHMO)，日本(JSMO),韩国(KSMO),马来西亚(MOS),菲律宾（PSMO）新加坡(SSO),台湾（TOS）和泰国（TSCO）。投票以科学证据为基础,独立于亚洲不同国家目前的治疗实践和治疗准入限制,在适当的时候进行了讨论。本指南手稿的目的是为亚洲不同地区子宫内膜癌患者的管理优化和协调提供指导。借鉴西方和亚洲试验提供的证据，同时尊重临床表现的变化，诊断实践，包括分子谱分析和获得治疗选择的差异，包括药物批准和报销策略。
